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ABSTRACT 
Objective: The present study was carried out to investigate and provide an overview of the pharmacokinetics, bio-equivalence and tissue residues 
of colistin in two oral tested products, BAC-LiquidoP®P (Interchemi Co.) and Coline-LP®P (Medmac Co.) in healthy broiler chickens. 
Methods: The comparative pharmacokinetics, bio-equivalence, blood and tissue residues of BAC-LiquidoP® P and Coline-LP®P in broiler chickens was 
studied after oral administration of both products in a dose of 100.000 IU colistin base/kg. b. wt once daily for 5 consecutive days.  
Results: Colistin in both products obeyed a two compartments open model following I. V administration. The disposition kinetics of BAC-LiquidoP®P 
and Coline-LP® P following oral administration of 100.000 IU colistin base/kg. b. wt revealed that the maximum blood concentration [CRmaxR.] were 5.10 
and 4.95 µg/ml and attained at [tRmax.R] of 5.90 and 6.40 h, respectively. Colistin in BAC-LiquidoP®P and Coline-LP® P was eliminated with half-lives [tR1/2βR] 
equal to 3.15 and 2.89 h, respectively. The mean systemic bioavailability of colistin in BAC-LiquidoP®P and Coline-LP®P following oral administration in 
healthy chickens was 3.75 and 4.05%, respectively. The blood (µg/ml) and tissue (µg/g) residues of Coline-L P®P and BAC-LiquidoP®P following repeated 
oral administrations showed that liver, kidney; lung, breast, and thigh muscles contained the limited colistin residues. Colistin in both preparations 
was completely disappeared from all tissues at 24 h following the last oral dose (except liver 48 h).  
Conclusion: It was concluded that Coline-LP® P is bioequivalent to BAC-LiquidoP®P since CRmax testR/CRmax referenceR and AUCRtestR/AUCRreferenceR ratios were 0.97 and 
1.06, respectively. Chickens should not be slaughtered for human consumption within treatment and could be consumed after the discontinuation of 
the treatment (except liver, withdrawal time 48 h) of either BAC-LiquidoP® P or Coline-LP® P. 
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INTRODUCTION 
Antibiotics are normally administrated via feed or drinking water by 
veterinarians for therapy, prophylaxis and as a growth promoter in 
chickens. As a result, there is concern that residues of antibiotics may 
be retained in tissues from treated birds. Therefore, it is essential to 
obtain data for the target tissues for these drugs in chickens [1, 2].  
Colistin, also known as polymyxin E, is a polypeptide antibiotic produced 
in culture broth of the aerobic spore-forming rod Bacillus Polymyxa Var. 
colistinus that can bind to membrane phospholipid of gram-negative 
bacteria to produce its strong effect against bacteria such as Escherichia 
coli, Pseudomonas aeruginosa, Bacillus, Salmonlla and Hemophilus [3]. 
In recent years, many bacterial strains developed strong resistance 
toward multiple drugs and antibiotics. Under such circumstances, 
colistin sulfate provides an effective treatment alternative to combat 
gram-negative bacteria that are sensitive to this antibiotic. Colistin 
sulfate binds to the bacterial lipopolysaccharide outer membrane and 
bacterial endotoxins leading to inhibition of the production and 
deactivation of bacterial endotoxins. Colistin sulfate is a chemical that is 
very effective in treating bacterial infections, especially those caused by 
multiple-drug-resistant gram-negative bacteria [4].  
The ability of each antibiotic in this group to kill these bacteria varies 
[5]. Polymyxins B and E (colistin) are not absorbed from the intestine 
[6]. Previous studies showed no effect on reproductive ability, 
developmental toxicity or gene toxicity for colistin [7]. Bioavailability 
and bioequivalence studies play an important role in determining 
therapeutic efficacy to register the generic drug products according to 
the Food and Drug Administration (FDA) regulations [8].  
The main purpose of this study is to investigate and provide an 
overview of the pharmacokinetics, bioequivalence and tissue 
residues of colistin in two oral tested products, BAC-LiquidoP®P and 
Coline-LP® P in healthy broiler chickens. 
MATERIALS AND METHODS 
Drugs 
BAC-LiquidoP® P: is manufactured by Ascor Chimici, Italy. It is 
dispensed as an oral solution. Each one ml contains colistin sulphate 
2,400,000 IU. 
Coline-LP® P: is manufactured by Medmac, Amman, Jordan. It is 
dispensed as an oral solution. Each one ml contains colistin sulphate 
2,400,000 IU. 
Experimental design 
Fifty clinically normal Hubbard chickens of 2 mo age, weighing 
2000-2250 g were selected from Tanta Poultry Farm, Egypt. They 
were kept individually in cages, within a ventilated, heated room (20 
°C) and 14 h of daylight. They received a standard commercial ration 
free from any antibiotics for 30 d before starting the experiments (to 
withdraw any antibiotic residues) and water ad Libitum. All 
procedures involving animals were reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) of Cairo 
University. 
Pharmacokinetics and Bioequivalence study 
Twenty clinically normal Hubbard chickens were used to study the 
pharmacokinetics of BAC-LiquidoP® P and Coline-LP® Pafter oral 
administration. Chickens were divided into two groups. The first 
group (10 chickens) was used to study the pharmacokinetics and 
bioequivalence of BAC-LiquidoP® P. The 2PndP group (10 chickens) was 
used to study the pharmacokinetics and bioequivalence of Coline-LP® P. 
Each chicken in both groups was injected intravenously with 25.000 
IU colistin base/kg. b. wt (from colistin methanesulphonate, Sigma 
AldrichP®P). Chickens were left for 15 d to ensure complete excretion 
of the antibiotic from their bodies. Then chickens from both groups 
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were administered orally (intra-crop) with BAC-Liquido® and 
Coline-L®in a dose of 100,000 IU colistin base/kg. b. wt, respectively.  
Tissue residues study 
Thirty clinically normal Hubbard chickens of 2-3 mo age, weighing 
about 2200-2450 g, were selected randomly from Tanta Poultry 
Farm, Egypt. Chicken was fed on a balanced ration free from 
antibiotic for 2 w (to withdraw any antibiotic residues) and water ad 
Libitum. 
Tissue residue of colistin in BAC-Liquido® (3rd group = 15 chickens) 
and Coline-L® (4th group = 15 chickens) were determined following 
repeated oral administrations of 100.000 IU colistin base/kg. b. wt 
for BAC-Liquido® and Coline-L®, respectively once daily for five 
consecutive days. After the end of the fifth day of repeated oral 
administrations, three chickens were slaughtered at 24, 48, 72, 96 
and 120 h for both groups, respectively. 
Blood and tissue sample 
One ml of blood was collected from wing vein after a single 
intravenous or oral administration of both drugs (groups 1 and 2) at 
intervals of 5, 15, 30 min, 1, 2, 4, 6, 8, 12 and 24 h. Blood samples 
were collected in dry centrifuge tubes. Serum was separated by 
centrifugation (2000 r. p. m./10 min) and stored at-20 °C until 
colistin assay. 
After the end of the fifth day of repeated oral administrations of 
BAC-Liquido® and Coline-L®
Petri dishes (120 X 20 mm) with the flat ad even bottoms were 
placed on a levels glass plate, and about 25 ml of inoculated medium 
was added to each dish by using a sterile cylinder (25 ml capacity) to 
form a thin layer of uniform thickness. After complete solidification, 
six wells were made on the surface of inoculated agar using stainless 
steel cylinder with sharp edges (10±0.1 mm length, 8±0.1 mm 
outside diameter, and 6±0.1 mm inside diameter) careful vertical 
punching creates wells that were clean and symmetric. A paper grid 
system under the plate facilitates the even spacing of the wells that 
allows for the triplicate determination of standards and samples. 
, three chickens were slaughtered at 24, 
48, 72, 96 and 120 h, from each slaughtered chicken, blood, lung, 
liver, kidney, and muscles were taken for drug assay. Samples were 
frozen and stored at-20 °C until colistin assay. 
Analytical procedure 
Arret et al., 1971 [9] described and modified by Tsai and Konda, 
2001 [10]. a cylinder plate diffusion assay technique which used 
with a single layer of medium agar II (Difco). About 1 ml of the spore 
suspension of Bordetella bronchiseptica (ATCC 4617) obtained from 
the Department of Microbiology, Faculty of Veterinary Medicine, 
Cairo University, Egypt. The organism was added to 100 ml agar II 
(at 55-60 °C). The mixture was shaken thoroughly till complete 
mixing of the test organism with the agar.  
Three plates were used for each sample; three wells on each plate 
were filled with the reference concentration (5 µg of colistin/ml free 
serum or phosphate buffer). The other three wells were filled with 
the sample (serum or organ homogenate). The plates were 
incubated at 37 °C for 16–18 h. The diameter of each inhibition zone 
was measured (mm) and plotted in semilogarithmic paper using 
concentration in (µg/ml) and the diameter of the zone of inhibition 
(mm). The standard curves were drawn through these points. The 
serum and tissue residues concentrations were obtained. 
Pharmacokinetic and statistical analysis 
The pharmacokinetic parameters of colistin were calculated by using a 
non-compartmental software program (WinNonlin® software, version 
5.2, Phar sight Corporation, NC, USA). The area under the serum 
concentration–time curve (AUC) was calculated using the trapezoidal 
rule with extrapolation to infinity. The maximum concentration (Cmax) 
and the corresponding peak time (tmax) were determined by the 
inspection of the individual drug serum concentration–time profiles. The 
slope of the terminal phase of the time–concentration curve was 
determined by linear regression and converted to an elimination half-life 
(t1/2β
Bioavailability 
The rate of absorption after oral administration was determined by 
comparing the area under the serum concentration-time curve 
(AUC) oral with that obtained following intravenous injection (AUC) 
i. v. in the same chicken. 






















 = Dose of oral administration. 
Bioequivalence 
The following equation according to FDA regulation [8] was 
performed to prove that the tested product is bioequivalent to the 
reference product in the study:  
 
Where: this ratio ranges from 0.85 to 1.25, this indicates that the test 
product Coline-L® is bioequivalent to the reference product BAC-
Liquido®
Data were expressed as mean±SE and were statistically analyzed using 
analysis of variance. Mean comparisons were performed using Tukey’s 
test. The differences were considered significant when p<0.05. These 
calculations were performed using Prism 5.0 (GraphPad). 
. 
 
Table 1: Pharmacokinetic parameters of colistin in BAC-Liquido® and Coline-L®
Parameter 
 following IV administration of 25.000 IU colistin base/kg. 
b.wt in broiler chickens (n = 10), mean±SE 
Unit G1 BAC-Liquido G2 Coline-L® ® 
C ° µg/ml 230.00±4.50 225.00±6.60 
t h 1/2α 0.16±0.08 0.11±0.06 
V L/kg c 1.50±0.18 1.70±0.25 
V L/kg d(area) 2.40±0.60 2.70±0.75 
V L/kg dss 2.75±0.45 2.45±0.60 
K h12 0.75±0.06 -1 0.95±0.08 
K h21 0.67±0.08 -1 0.71±0.07 
t h 1/2β 0.50±0.08 0.45±0.06 
Cl L/kg/h B 83.37±4.45 87.77±6.40 
AUC µg. h/ml 0-∞ 436.30±12.20 430.90±7.00 
C ° = Drug concentration in serum at zero time immediately after a single  intravenous injection; AUC0-∞ = area under the concentration-time curve 
from zero up to ∞ with extra polation of the terminal phase; t½β  = half-life of the elimination; Vc= volume of the central compartment; Vdarea= 
Volume calculated by the area method; Vdss = apparent volume of distribution at steady-state; ClB = clearance from the body. K12 = First order 
transfer rate constant for drug distribution from central to the peripheral compartment; K21 =First order transfer rate constant for drug distribution 
from peripheral to central compartment. 
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RESULTS 
The mean serum concentration-time curve of colistin in BAC-
Liquido® and Coline-L® following I. V and oral administration is 
plotted and presented graphically in fig. (1, 2). The pharmacokinetic 
parameters of colistin in BAC-Liquido® and Coline-L® following I. V. 
administration of 25.000 IU colistin base/kg. b. wt in broiler 
chickens were calculated and showed in the table (1). The 
pharmacokinetic parameters of colistin in BAC-Liquido® and Coline-
L®
The disposition kinetics of colistin in BAC-Liquido
 after oral administration of 100.000 IU colistin base/kg. b. wt in 
broiler chickens were calculated and showed in the table (2).  
® and Coline-L® 
following oral administration of 100.000 IU colistin base/kg. b. wt 
revealed that the maximum blood concentration [Cmax.] were 5.10 and 
4.95 µg/ml and attained at [tmax.] of 5.90 and 6.40 h, respectively. Colistin 
in BAC-Liquido® and Coline-L® was eliminated with half-lives [t1/2β] 
equal to 3.15 and 2.89 h, respectively. The mean systemic bioavailability 
of colistin in BAC-Liquido® and Coline-L® following oral administration 
in broiler chickens was 3.75 and 4.05%, respectively. The oral 
bioavailability of BAC-Liquido® and Coline-L®
Blood and tissue residues of colistin in BAC-Liquido
 indicated a poor 
absorption from GIT which indicated that both formulations are advised 
to be given orally in the case of acute bacterial infections in GIT. 
® and Coline-L® 
in slaughtered chickens following repeated oral administrations of 
100.000 IU colistin base/kg. b. wt once daily for 5 consecutive days 
are recorded in the table (3). The represented data revealed a poor 
spread distribution of colistin in both BAC-Liquido® and Coline-L®
 
 in 
lung, liver, kidney, and muscles (Breast and Thighs).
Table 2: Pharmacokinetic parameters of colistin in BAC-Liquido® and Coline-L® following oral administration of 100.000 IU colistin 
base/kg. b. wt in broiler chickens (n = 10), mean±SE 
Parameter Unit G1 BAC-Liquido G2 Coline-L® ® 
k hab 2.86±0.80 -1 3.44±0.50 
t h 1/2 ab 0.24±0.09 0.20±0.06 
t h 1/2β 3.15±0.35 2.89±0.40 
t h max. 5.90±0.80 6.40±0.95 
C µg/ml max. 5.10±0.35 4.95±0.80 
AUC µg. h/ml 0-t 16.40±1.40 17.45±2.00 
Bioavailability % 3.75±0.75 4.05±0.60 
Bio-Equivalent  
AUC Ratio  1.06 
C Ratio max. 0.97 
Cmax = maximal concentration; tmax = when the maximal serum concentration is reached; AUC0-t = area under serum concentration time curve; t1/2β  = 
Elimination half-life; Kab = first-order absorption rate constant; t1/2 ab
 
 = The absorption half-life (h). 
Table 3: Blood levels (µg/ml) and tissue concentrations (µg/g) of colistin in BAC-Liquido® and Coline-L®
Blood and 
Tissues 
 following repeated oral 
administrations of 100.000 IU colistin base/kg. b. wt once daily for five consecutive days in broiler chickens (n=3), mean±SE 
Time after the last dose (h) 





















Blood N. D N. D N. D N. D N. D N. D N. D N. D N. D N. D 
Lung N. D N. D N. D N. D N. D N. D N. D N. D N. D N. D 
Liver 3.60 3.30 0.30 0.15 N. D N. D N. D N. D N. D N. D 























N. D = Not detected, After the end of the fifth day of repeated oral administrations, three chickens were slaughtered at 24, 48, 72, 96 and 120 h. 
 
 
Fig. 1: Semilogarithmic plot showing the serum concentrations-
time profile of colistin in BAC-Liquido®
 
 following intravenous 
and oral administration in broiler chickens (n=10) 
 
Fig. 2: Semilogarithmic plot showing the serum concentrations-
time profile of colistin in Coline-L®
 
 following intravenous and 
oral administration in broiler chickens (n=10) 
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DISCUSSION 
Antibiotics are widely used as veterinary drugs or as feed additives 
to promote growth. Some studies had induced pharmacokinetic data 
in poultry [11-15].  
Colistin in both formulations following I. V. administration obeyed a 
two compartments open model, this indicated that colistin 
distributed in the chickens in two compartments; a central one 
which represents blood and highly perfused organs (kidney–liver–
spleen–heart) and a 2nd peripheral compartment which represented 
by skin and connective tissues. Following I. V. administration in a 
dose of 25.000 IU colistin base/kg. b. wt, colistin is obeyed a two-
compartment open model with high volume of distribution 
(exceeded than one L/kg) calculated by extrapolation [VdB] and 
steady state [Vdss] method are factors made colistin is highly 
distributed in all body tissues; a factor revealed that colistin, when 
given by IV injection, is the drug of choice for attacking the systemic 
infections caused by sensitive organisms. [16] reported that I. V. 
administration of 5 mg colistin/kg. b. wt in ewes resulted in a serum 
half-life of 2.7–4.3 h and a Vd
In man, absorption of polymyxins from the gastrointestinal tract is 
slow and limited so that ordinary oral doses do not produce detectable 
plasma concentrations. The same may be true for other monogastric 
animals. Under normal conditions, less than 0.5% of the oral 
administered dose is absorbed from the gastrointestinal tract [20].  
 of 1.29 L/kg. There is limited 
information on the mechanism by which colistin is formed from 
colistin methanesulphonate in vitro and in vivo [17, 18]. A 
statistically significant difference was not found between the 
calculated pharmacokinetic parameters in the investigated groups, 
these results were showing the bioequivalence of the two 
formulations according to the criteria established by FDA [8]. 
Bioequivalence refers to a comparison between generic 
formulations of a drug or a product in which a change has been 
made in one or more of the ingredients or in the manufacturing 
process, and a reference dosage form of the same drug [19].  
EMEA 2002 [21] investigated that hens were orally given colistin 
sulphate at dosages of 25 mg and 50 mg/kg body weight, the serum 
level in the 25 mg group was highest after 1 hour (1.5 mcg/ml); 
thereafter, it decreased by time and was no longer detectable 6 h 
post administration. In the bile, the highest colistin concentration 
was measured at the first hour (2.5 mcg/g), however, after 6 h no 
concentrations were detectable. The serum level in the 50 mg group 
was highest after 2 h (10.2 mcg/ml), decreasing gradually thereafter 
and 8 h post administration, no concentrations were detectable. In 
the bile, colistin showed the highest concentrations 2 h post 
administration, however, 8 h post administration, no concentrations 
were detectable. Also, EMEA 2002 [21] investigated that the 
pharmacokinetic data in the target species confirmed that colistin 
sulphate was poorly absorbed after oral administration to calves, 
pigs and rabbits and serum concentrations were generally 
undetectable in the species. In chickens, residues in serum were 
detectable for up to 6 h after administration in the drinking water. 
Colistin could not be determined in all tissues tested in all time 
intervals after the last dose. This indicated that colistin is not 
absorbed after oral route in concentration could be detected [22]. In 
the same direction, [6] investigated that colistin residues were not 
detected after the drug administration by the oral route but could be 
detected in the yolk until 8 d after intramuscular injection. 
EMEA 2002 [21] and FAO/WHO 2006 [2] recorded that residues of 
colistin could be detectable in serum for up to 24 h after 
intramuscular or intravenous administration to calves and dairy 
cows. In calves, bioavailability approached 100% after 
intramuscular administration. In ewes, peak serum concentrations 
of 8-20 µg/ml were achieved 2 h after intramuscular injection. 
Residues in eggs from hens given colistin sulphate in the drinking 
water were below the limit of detection of the analytical method. 
Significant residues were found up to 8 d in eggs following 
intramuscular injection to hens. 
In the present work, the tissue residues of colistin in Colin-L® and 
BAC-Liquid®
CONCLUSION 
 at all times were below the MRLs approved by [2].  
Based on the above pharmacokinetic and statistical results that 
calculated in the current study, we concluded that Coline-L®is 
bioequivalent to BAC-Liquido® since Cmax test/Cmax. Reference and 
AUCtest/AUCreference
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